1. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series
- Author
-
M.A. Middelkamp‐Hup, L.A.A. Gerbens, A.L. Bosma, Ph.I. Spuls, Dermatology, APH - Methodology, APH - Personalized Medicine, AII - Inflammatory diseases, and APH - Quality of Care
- Subjects
Moderate to severe ,Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Concise Report ,Dermatology ,Disease ,Antibodies, Monoclonal, Humanized ,Dermatitis, Atopic ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,medicine ,Humans ,Lactation ,Lack of knowledge ,In patient ,Concise Reports ,business.industry ,Pregnancy Outcome ,Antibodies, Monoclonal ,Atopic dermatitis ,medicine.disease ,Ciclosporin ,Dupilumab ,Withholding Treatment ,030220 oncology & carcinogenesis ,Fertilization ,Female ,Dermatologic Agents ,business ,medicine.drug - Abstract
Dupilumab is a relatively new treatment option for patients with moderate to severe atopic dermatitis. There is a lack of knowledge about the effects of treatment with dupilumab during conception for both men and women, as well as during pregnancy and lactation in women. We report four patients (two men, two women) who expressed a wish to conceive during treatment with dupilumab in daily practice. Both men conceived during dupilumab treatment, while the two women discontinued dupilumab because of anticipated pregnancy. Apart from disease flares in both of the patients who discontinued treatment, no complications were reported concerning the ability to conceive, the course of the pregnancy or the fetal outcome. We present an overview of the current available literature on dupilumab during conception, pregnancy and lactation, which can guide considerations for patients on dupilumab wishing to conceive a child. Until more data are available, preference should be given to treatment with topical corticosteroids, phototherapy, systemic corticosteroids and ciclosporin.
- Published
- 2021